3 Dividend-Paying Pharmaceutical Stocks Rated Strong Buy In The POWR Ratings
Article By:
Rick Ristov
Read
Thursday, December 16, 2021 4:16 AM EST
We think dividend-paying quality pharmaceutical stocks Pfizer Inc, Merck & Co., Inc, and Bristol-Myers Squibb Company could be solid additions to one’s portfolio now to secure a steady income stream.
Why Hospitals And Healthcare Systems Should Consider Private Credit
Article By:
Rick Ristov
Read
Thursday, November 4, 2021 12:02 PM EST
The interest rate paid on private credit loans is floating rate and as such will increase as interest rates do, consequently providing protection from rising interest rates.
Saliva Test For COVID-19 With "Less Than 1 Second" Results Enters Trial Phase In Israel
Article By:
Tyler Durden
Read
Thursday, August 13, 2020 10:37 PM EST
Sure to be welcome news for those eager to return to work and school, an Israeli hospital is hosting clinical trials for a new "instant" test which utilizes saliva, instead of the more invasive and uncomfortable deep nasal swab.
Is Defensive Sector Leadership Forecasting Slower Growth?
Article By:
Charlie Bilello
Read
Tuesday, November 25, 2014 5:21 PM EST
Utilities and Health Care. These are the top two sectors in the S&P 500 this year, which may come as a surprise to many as we’re being told that economic growth is set to accelerate.
In this article: XLU
CPHD Receives FDA Clearance For Xpert Flu/RSV XC; SUPN Receives Issuance Of Fifth US Patent
Article By:
BioMedReports
Read
Tuesday, November 25, 2014 3:27 AM EST
CPHD announced it has received clearance from the U.S. FDA to market its Xpert®, SUPN, announced the issuance of a fifth patent (number 8,889,191) by the United States Patent and Trademark Office (USPTO), its novel once-daily extended-release topiramate product.
EC Holiday Fever Takes Hold Of Stock Investors, But A Pullback Is Needed
Article By:
Sabrient Systems
Read
Monday, November 24, 2014 3:15 PM EST
Nothing goes up in a straight line, not even during the holidays, so a near-term market pullback would be a healthy way to prevent a steeper correction in January.
OMED Offers Data From Demcizumab; CELG Receives Positive CHMP Opinion For OTEZLA
Article By:
BioMedReports
Read
Monday, November 24, 2014 3:23 AM EST
OMED a clinical-stage company presenting data in two posters, highlighting the company's translational research and biomarker efforts for its tarextumab. CELG announced that the (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for OTEZLA.
AEZS Adds Hollings Cancer Center To Multi-National Phase 3 Trial; MRNA And Mirna Amend License Agreement
Article By:
BioMedReports
Read
Friday, November 21, 2014 3:18 AM EST
AEZS announced the opening of a new clinical site at the Hollings Cancer Center of the Medical University of South Carolina. MRNA announced they have amended their license agreement regarding the development and commercialization of microRNA-based therapeutics.
The $1 Million Baby Blue Cross Refuses To Pay The Bill
Article By:
Martin Armstrong
Read
Friday, November 21, 2014 1:44 AM EST
The Million Dollar Baby Blue Cross Refuses to Pay the Bill. Heath Insurance is getting to be a real fraud.
PTCT Spinal Muscular Atrophy Program Enters Phase 1b/2a Trial; OMER Inhibits Thrombus Formation
Article By:
BioMedReports
Read
Thursday, November 20, 2014 6:37 AM EST
PTC Therapeutics and Omeros each announce new study phase.
E Merrimack Receives Fast Track For Pancreatic Cancer Drug
Article By:
Terry Chrisomalis
Read
Wednesday, November 19, 2014 4:29 PM EST
The reason the FDA gave MACK Fast Track approval is because there are no current therapies for pancreatic cancer -- the drug meets an unmet medical need.
Health Care REIT Completes HealthLease Transaction
Article By:
Business Wire
Read
Wednesday, November 19, 2014 12:00 PM EST
Health Care REIT, Inc. announced today the completion of the previously announced acquisition of HealthLease Properties REIT (“HealthLease”).
In this article: HCN
ARWR Files For Regulatory Permission To Begin Phase 1 Trial Of RNAi; TPIV Announces Phase II Clinical Trials With VGTI Florida
Article By:
BioMedReports
Read
Wednesday, November 19, 2014 3:29 AM EST
ARWR today announced that it recently filed an application for approval to begin a Phase 1 clinical trial of its RNAi-based therapeutic candidate.TPIV. is pleased to announce a new collaborative research agreement with The Vaccine & Gene Therapy Institute of Florida.
The Fournier Transform
Article By:
Angry Bear
Read
Wednesday, November 19, 2014 3:13 AM EST
On health care, we needed a market-driven plan that decreases the percentage of uninsured Americans without convoluting the U.S. health care system.
Actavis Strikes $66 Billion Deal For Botox Maker Allergan
Article By:
Zacks Investment Research
Read
Tuesday, November 18, 2014 5:01 PM EST
With the Allergan acquisition, Actavis will be able to strengthen its global presence especially in Canada, Europe and Southeast Asia and other high-value growth markets like China, India, the Middle East and Latin America.